Cancer Biomarker: refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer.
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
The laboratory diagnosis of infectious diseases has traditionally relied on recovery of pathogens in cultures and for many infections, this approach remains the standard of care. The developm...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
As reimbursement changes and healthcare moves towards value-based models, the clinical laboratory is faced with the challenge of redefining its value outside the cost per test. This session...
Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions fo...
Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. We combine the RNA- targeting CRISPR effector Cas13 with...
DATE: March 26, 2019TIME: 2:00pm PDT, 5:00pm EDT Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
DATE: March 5, 2019TIME: 10:00am PSTSingle cell analysis, starting with the earliest low parameter fluorescent experiments, helped define the major cell subsets of human ce...
DATE: March 5, 2019TIME: 09:00am PST, 12:00pm EST MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post tran...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
Small size, highly selective nature, flexible chemistry and ease of manufacturing make nucleic acid aptamers attractive for multiple applications in human diagnostics and drug discovery. &nbs...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
CRISPR-chip combines two powerful technologies ,CRISPR and Graphene, for rapid detection of nucleic acids. This talk will focus on design and fabrication of CRISPR-chip and its potential util...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
The laboratory diagnosis of infectious diseases has traditionally relied on recovery of pathogens in cultures and for many infections, this approach remains the standard of care. The developm...
Regulatory requirements for verification and validation are complex and often cause confusion among clinical laboratorians, especially in regards to quantitative molecular assays. This presen...
As reimbursement changes and healthcare moves towards value-based models, the clinical laboratory is faced with the challenge of redefining its value outside the cost per test. This session...
Management of complex quality control (QC) data is essential to insure high quality patient care and maintain regulatory compliance within clinical laboratories. Robust software solutions fo...
Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. We combine the RNA- targeting CRISPR effector Cas13 with...
DATE: March 26, 2019TIME: 2:00pm PDT, 5:00pm EDT Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
DATE: March 5, 2019TIME: 10:00am PSTSingle cell analysis, starting with the earliest low parameter fluorescent experiments, helped define the major cell subsets of human ce...
DATE: March 5, 2019TIME: 09:00am PST, 12:00pm EST MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post tran...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
Small size, highly selective nature, flexible chemistry and ease of manufacturing make nucleic acid aptamers attractive for multiple applications in human diagnostics and drug discovery. &nbs...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
Follow
